Comparative Pharmacology
Head-to-head clinical analysis: ENDURONYL FORTE versus HYDROMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURONYL FORTE versus HYDROMOX.
ENDURONYL FORTE vs HYDROMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enduronyl Forte is a combination of methyclothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, and deserpidine, a Rauwolfia alkaloid that depletes catecholamines from adrenergic nerve endings, resulting in reduced peripheral vascular resistance and CNS sedation.
Inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing water excretion.
Oral: Initial 2.5-5 mg once daily; increase as needed to maximum 20 mg once daily.
50-100 mg orally once daily; may increase to 200 mg/day for severe edema.
None Documented
None Documented
Terminal elimination half-life: 24-48 hours (avg. 36 h); due to long half-life, requires caution in renal impairment.
Terminal elimination half-life: 6-9 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Renal: ~50% unchanged; Biliary/Fecal: ~50% as metabolites and unchanged drug.
Renal: 70% unchanged via tubular secretion; biliary/fecal: <10%
Category C
Category C
Thiazide Diuretic + Rauwolfia Alkaloid
Thiazide Diuretic